

**IFITM2 Mouse mAb[5IKX]**

**Cat NO. :A37804**

**Information:**

Applications	Reactivity:	UniProt ID:	MW(kDa)	Host	Isotype	Size
WB,IHC,ICC/IF	H	Q01629	15	Mouse	IgG	100ul,200ul

**Applications detail:**

Application	Dilution
WB	1:1000-2000
IHC	1:100
ICC/IF	1:100
The optimal dilutions should be determined by the end user	

**Conjugate:**

UnConjugate

**Form:**

Liquid

**sensitivity:**

Endogenous

**Purification:**

Protein A purification

**Specificity:**

Antibody is produced by immunizing animals with a synthetic peptide at the sequence of human IFITM2.

**Storage buffer and conditions:**

Antibody store in 10 mM PBS, 0.5mg/ml BSA, 50% glycerol (buffer) .

Shipped at 4°C. Store at-20°C or -80°C.

Products are valid for one natural year of receipt.Avoid repeated freeze / thaw cycles.

**Tissue specificity:**

**Subcellular location:**

Cell membrane,Single-pass type II membrane protein. Lysosome membrane,Single-pass type II membrane protein.

Late endosome membrane,Single-pass type II membrane protein.

**Function:**

**Introduction:** **WB:** Western Blot **IP:** Immunoprecipitation **IHC:** Immunohistochemistry **ChIP:** Chromatin Immunoprecipitation **ICC/IF:** Immunocytochemistry/Immunofluorescence **F:** Flow Cytometry


**Cross Reactivity:** **H:** human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Ml:** mink **C:** chicken **Dm** D. melanogaster **X:** Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Hr:** horse

**For Research Use Only. Not For Use In Diagnostic Procedures.**

IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol (PubMed:33563656, PubMed:26354436). Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DENV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:33563656, PubMed:26354436, PubMed:33270927, PubMed:33239446). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33563656). Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436)..

## Validation Data:

### IFITM2 Mouse mAb[5IKX] Images



Western blot (SDS PAGE) analysis of extracts from HepG2 cells lysates. Using IFITM2 mouse mAb IgG [5IKX] at dilution of 1:1000 incubated at 4°C over night.

View more information on <http://naturebios.com>

**IMPORTANT:** For western blots, incubate membrane with diluted primary antibody in 1% w/v Milk, 1X TBST at 4°C overnight.